LLY
Eli Lilly and Company
LLY has the edge over MNKD overall, supported by stronger fundamentals and lower modeled downside.
MNKD
MannKind Corporation
MNKD's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MNKD Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Weak |
MNKD's revenue is currently strong, but its profitability, cash flow and balance sheet are weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
MNKD PE Valuation
MNKD has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 178x next year's earnings.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
MNKD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect MNKD to return to profit, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over MNKD on earnings quality, reporting a profit while its opponent remains loss making.
MNKD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.02 | — |
| Q3 2026 | -$0.23 | -330% |
| Q2 2026 | -$0.13 | -218% |
| Q1 2026 | -$0.07 | -170% |
| Q4 2025 | $0.02 | -80% |
| Q3 2025 | $0.10 | +25% |
| Q2 2025 | $0.11 | +120% |
| Q1 2025 | $0.10 | +150% |
| Q4 2024 | $0.10 | +$0.14 |
MNKD has swung to a loss: it lost $0.23 per share over the past year, after a profit the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over MNKD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over MNKD on profitability, with a higher operating margin.
MNKD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $101.9M | +24% |
| Q2 2026 | $109.4M | +43% |
| Q1 2026 | $90.2M | +15% |
| Q4 2025 | $112M | +46% |
| Q3 2025 | $82.1M | +17% |
| Q2 2025 | $76.5M | +5.7% |
| Q1 2025 | $78.4M | +18% |
| Q4 2024 | $76.8M | +31% |
MNKD's revenue has grown year over year for 17 quarters in a row: $102M last quarter, up 24% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.1% | -25 points |
| Q2 2026 | -0.3% | -7.2 points |
| Q1 2026 | -1.9% | -30 points |
| Q4 2025 | -6.9% | -41 points |
| Q3 2025 | 23% | +4.8 points |
| Q2 2025 | 6.9% | -16 points |
| Q1 2025 | 28% | +3.2 points |
| Q4 2024 | 35% | +21 points |
MNKD's operating margin was −2.1% last quarter, down 25 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over MNKD on cash generation, producing positive trailing cash flow while its opponent burns cash.
MNKD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37.8M | -268% |
| Q2 2026 | -$23.5M | -399% |
| Q1 2026 | -$7.2M | -$538K |
| Q4 2025 | -$10M | -150% |
| Q3 2025 | $22.5M | +184% |
| Q2 2025 | $7.8M | +810% |
| Q1 2025 | -$6.7M | -256% |
| Q4 2024 | $19.7M | +25% |
MNKD has burned cash in most quarters: −$78M over the past year, against $43M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over MNKD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
MNKD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +11M shares |
| 1 year | +2.7% | +8.5M shares |
| 3 years | -1.1% | -3.6M shares |
| 5 years | +28% | +70.3M shares |
| Available history | +55% | +113M shares |
MNKD has 320M diluted shares, up 2.7% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over MNKD on leverage, with a lower net debt burden relative to earnings.
MNKD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 19.7x | High |
| Q2 2026 | 8.9x | High |
| Q1 2026 | 8.5x | High |
| Q4 2025 | 5.5x | High |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -0.3x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.1x | Net Cash |
MNKD's net debt is about 20 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MNKD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.4 | Neutral |
| Stochastic | 63.7 | Neutral |
MNKD's weekly RSI is 55 (neutral) and its Stochastic is 64 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
MNKD PE vs Healthcare Sector
| Metric | MNKD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MNKD has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over MNKD on trend strength, trading above more of its moving averages.
MNKD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 18% above |
| 20 week MA | $3.82 | 8.9% above |
| 50 week MA | $4.00 | 4% above |
| 100 week MA | $4.48 | 7.1% below |
| 200 week MA | $4.62 | 10% below |
MNKD has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 10% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over MNKD on returns for 2026, with the stronger performance.
MNKD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.37 | $3.42 | +150% |
| 2021 | $3.42 | $4.46 | +30% |
| 2022 | $4.46 | $5.09 | +14% |
| 2023 | $5.09 | $3.64 | -28% |
| 2024 | $3.64 | $6.82 | +87% |
| 2025 | $6.82 | $5.79 | -15% |
| 2026 YTD | $5.79 | $4.16 | -28% |
MNKD has finished higher in four of the last six years, two of them by more than 50%. It's down 28% so far in 2026.